IP Verse

Blueprint Medicines patent opposition analysis

Get complete Patent Opposition Report for Blueprint Medicines

Comprehensive Analysis, Strategic Insights & Expert Evaluation – Stay Ahead in Your Patent Challenge.

Download Your Report Now

Latest patents of Blueprint Medicines opposed by its competitors

Explore Blueprint Medicines's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Patent NumberGrant DateTitleTotal Oppositions
EP3773589Nov 1, 2023Ret Inhibitor For Use In Treating Cancer Having A Ret Alteration1
EP3856341Sep 6, 2023Crystalline Forms Of (S)-1-(4-Fluorophenyl)-1-(2-(4-(6-(1-Methyl-1H-Pyrazol-4-Yl)Pyrrolo[2,1-F][1,2,4]Triazin-4-Yl)Piperazinyl)-Pyrimidin-5-Yl)Ethan-1-Amine And Methods Of Making1

Top competitors of Blueprint Medicines